Entellus Medical completes its Series D financing totaling $30MM

Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, has completed its Series D financing totaling $30MM. The Series D round was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences.

“This new investment gives us the resources needed to expand our product offering to the millions of sinusitis sufferers who are seeking lasting relief. The Entellus FinESS® Sinus Treatment provides a new option that minimizes the pain and recovery time compared to traditional sinus surgery, can also be done in the clinic and may reduce the need for antibiotics,” said Tom Ressemann, president and CEO of Entellus.

Ressemann said the latest round of funding will be used to expand their sales and customer support teams, and accelerate efforts to allow patients to be treated in an office-based setting. In addition, the funding will allow Entellus to launch its innovative technologies nationwide in 2010 and prepare to market internationally.

“We are excited to join Entellus Medical as an investor”, said Guido Neels, managing director at Essex Woodlands Health Ventures. “We believe FinESS is an important new medical device therapy that combines the opportunity to deliver immediate relief with lasting results for the patient, while reducing overall health care expenditures. We look forward to working with the excellent management team of Entellus Medical to realize the full potential of the company.” Guido Neels will join the board of directors of the company, effective immediately.